866-997-4948(US-Canada Toll Free)

Rectal Cancer - Pipeline Review, H2 2014

Published By :

Global Markets Direct

Published Date : Jul 2014

Category :

Cancer

No. of Pages : 105 Pages

Rectal Cancer - Pipeline Review, H2 2014

Summary

Global Markets Directs, Rectal Cancer - Pipeline Review, H2 2014, provides an overview of the Rectal Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rectal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Rectal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rectal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Rectal Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Rectal Cancer - Overview 8
Pipeline Products for Rectal Cancer - Comparative Analysis 9
Rectal Cancer - Therapeutics under Development by Companies 10
Rectal Cancer - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Rectal Cancer - Products under Development by Companies 14
Rectal Cancer - Companies Involved in Therapeutics Development 15
GlaxoSmithKline plc 15
Celltrion, Inc. 16
Hanwha Chemical Co., Ltd. 17
Eisai Co., Ltd. 18
Peregrine Pharmaceuticals, Inc. 19
Synta Pharmaceuticals Corp. 20
Nanobiotix 21
Cerulean Pharma, Inc. 22
Incuron, LLC 23
Karyopharm Therapeutics, Inc. 24
Akshaya Bio Inc. 25
AbbVie Inc. 26
Rectal Cancer - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
E-7820 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CRLX-101 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ISOMC-091 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ganetespib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
mepacrine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
bavituximab - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
veliparib - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
GSK-2256098 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
selinexor - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
HD-204 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
NBTX-IV - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
NBTXR-3 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
bevacizumab biosimilar - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Vaccine to Target MUC1 for Cancer - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Rectal Cancer - Recent Pipeline Updates 67
Rectal Cancer - Dormant Projects 100
Rectal Cancer - Product Development Milestones 101
Featured News & Press Releases 101
Mar 18, 2014: Cerulean Announces First Patient Dosed in Phase 1b/2 Trial of CRLX101 in Combination with Chemotherapy and Radiation in Neoadjuvant Rectal Cancer 101
Nov 03, 2012: Merck KGaA Ceases Supply Of Cancer Drug Erbitux To Greek Hospitals 102
Sep 06, 2012: NCCN Oncology Research Program Receives Funding From GSK To Evaluate Clinical Effectiveness Of Trametinib 102
Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy 103
Appendix 104
Methodology 104
Coverage 104
Secondary Research 104
Primary Research 104
Expert Panel Validation 104
Contact Us 105
Disclaimer 105

List of Tables
Number of Products under Development for Rectal Cancer, H2 2014 8
Number of Products under Development for Rectal Cancer - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Rectal Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 15
Rectal Cancer - Pipeline by Celltrion, Inc., H2 2014 16
Rectal Cancer - Pipeline by Hanwha Chemical Co., Ltd., H2 2014 17
Rectal Cancer - Pipeline by Eisai Co., Ltd., H2 2014 18
Rectal Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2014 19
Rectal Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 20
Rectal Cancer - Pipeline by Nanobiotix, H2 2014 21
Rectal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2014 22
Rectal Cancer - Pipeline by Incuron, LLC, H2 2014 23
Rectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 24
Rectal Cancer - Pipeline by Akshaya Bio Inc., H2 2014 25
Rectal Cancer - Pipeline by AbbVie Inc., H2 2014 26
Assessment by Monotherapy Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 30
Number of Products by Stage and Mechanism of Action, H2 2014 33
Number of Products by Stage and Route of Administration, H2 2014 35
Number of Products by Stage and Molecule Type, H2 2014 37
Rectal Cancer Therapeutics - Recent Pipeline Updates, H2 2014 67
Rectal Cancer - Dormant Projects, H2 2014 100

List of Figures
Number of Products under Development for Rectal Cancer, H2 2014 8
Number of Products under Development for Rectal Cancer - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Early Stage Products, H2 2014 13
Assessment by Monotherapy Products, H2 2014 27
Number of Products by Top 10 Target, H2 2014 28
Number of Products by Stage and Top 10 Target, H2 2014 29
Number of Products by Top 10 Mechanism of Action, H2 2014 31
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 32
Number of Products by Top 10 Route of Administration, H2 2014 34
Number of Products by Stage and Top 10 Route of Administration, H2 2014 35
Number of Products by Top 10 Molecule Type, H2 2014 36
Number of Products by Stage and Top 10 Molecule Type, H2 2014 37

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *